Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer.
In conclusion, small tumor size and long doubling time of each target lesion can be a prognostic marker to predict the responsiveness to sorafenib in RAI-refractory DTC patients.
PMID: 31006722 [PubMed - as supplied by publisher]
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research
More News: Cancer | Cancer & Oncology | Endocrinology | Iodine | Skin | Statistics | Thyroid | Thyroid Cancer